124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
May 2005 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Truncated LTBP-1 disrupts TGF-beta signaling, affecting hair growth.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
8 citations
,
December 2023 in “International Journal of Molecular Sciences” Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.
54 citations
,
January 2023 in “Signal Transduction and Targeted Therapy” New therapies are being developed that target integrin pathways to treat various diseases.
October 2023 in “European journal of dermatology/EJD. European journal of dermatology” Injectable platelet-rich fibrin can safely and effectively treat melasma.
8 citations
,
August 2015 in “European Journal of Clinical Pharmacology” Rivaroxaban may cause hair loss.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
July 2023 in “International journal of trichology” Injectable platelet-rich fibrin may stop hair loss from Discoid lupus erythematosus.
41 citations
,
December 2008 in “Current Opinion in Ophthalmology” Certain eye surgery complications can be managed effectively, especially in patients who have used specific prostate medications.
3 citations
,
August 2024 in “Clinical Cosmetic and Investigational Dermatology” The 1927 nm fractional thulium laser effectively treats acne by targeting and improving affected skin areas.
51 citations
,
May 2008 in “Mycoses” Terbinafine HCl nail solutions with DDAIP HCl are more effective than current treatments for nail infections.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
November 2022 in “LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)” Platelet-rich fibrin speeds up burn wound healing in rabbits.
January 2022 in “Essentials in ophthalmology” Tamsulosin increases the risk of floppy iris syndrome during cataract surgery.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
1 citations
,
December 2022 in “Archives of Dermatological Research” Fluid Platelet-Rich Fibrin (PRF) is more effective and faster at improving acne scars than Platelet-Rich Plasma (PRP), with similar mild side effects.
December 2022 in “Pakistan Journal of Medical and Health Sciences” Tofacitinib effectively treats Alopecia Areata.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
10 citations
,
November 2020 in “American Journal Of Pathology” Integrin β1 is crucial for liver structure and function, preventing fibrosis.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
6 citations
,
May 2021 in “Journal of Health Sciences” Intravenous delivery of autologous activated platelet-rich plasma is safe.